Correction:  MYC  amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy

Toril Holien; Kristine Misund; Oddrun Elise Olsen; Katarzyna Anna Baranowska; Glenn Buene; Magne Børset; Anders Waage; Anders Sundan

doi:10.18632/oncotarget.26373

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy

PDF | How to cite

Oncotarget. 2018; 9:36048-36048. https://doi.org/10.18632/oncotarget.26373

Metrics: PDF 1788 views | ?

Toril Holien¹, Kristine Misund¹, Oddrun Elise Olsen¹, Katarzyna Anna Baranowska¹, Glenn Buene¹, Magne Børset^1,2, Anders Waage^1,3 and Anders Sundan^1,4

¹ K.G. Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
² Department of Immunology and Transfusion Medicine, St. Olav’s University Hospital, Trondheim, Norway
³ Department of Hematology, St. Olav’s University Hospital, Trondheim, Norway
⁴ CEMIR (Centre of Molecular Inflammation Research), Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

Published: November 13, 2018

This article has been corrected: The legends for figures 1 and 2 were accidentally switched. The corrected figure legends are given below:

Figure 1: Expression of MYC in myeloma cell lines correlated positively with sensitivity to MYC inhibition. The IC50- values of the MYC inhibitor 10058-F4 calculated from the results shown in Supplementary Figure 2 was compared with A. MYC mRNA values or B. MYC/GAPDH relative protein levels. The slope and R²-values are shown in the plots.

Figure 2: MYC gene copy numbers determine expression of MYC mRNA and protein in myeloma cell lines. In a panel of myeloma cell lines the levels of MYC gene copy numbers as measured by PCR was related to A. MYC mRNA measured using nCounter, and B. MYC protein levels measured using immunoblotting and normalized to GAPDH. The slope and R²-values are shown in the plots.

Original article: Oncotarget. 2015; 6:22698-22705. DOI: https://doi.org/10.18632/oncotarget.4245.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26373

Publication Alerts

Corrections:

Correction: MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy